Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
Madrigal presented new data at the EASL Congress 2026 showing Rezdiffra reduces cardiovascular risk markers, including LDL-C and Lp(a), in MASH patients regardless of statin use. Secondary analysis of the Phase 3 MAESTRO program showed that among statin-treated patients, 44.4% with baseline LDL-C ≥70mg/dL shifted to <70mg/dL at week 52, while 50.0% of those with baseline LDL-C ≥100mg/dL shifted below that threshold. In patients with compensated MASH cirrhosis, Rezdiffra improved the ANTICIPATE-NASH risk score by up to 37.6% over two years, reducing the proportion of high-risk patients from 75% at baseline to 54.5% at Year 2.
Key figures
- Drug Name
- Rezdiffra (resmetirom)
- Statin treated n
- 473
- Non statin treated n
- 493
- High risk csph year1 pct
- 60.3%
- High risk csph year2 pct
- 54.5%
- High risk csph baseline pct
- 75%
- German registry eligible pct
- 20%
- Liver stiffness reduction pct
- 49%
- Anticipate nash score decline pct
- 37.6%
- Liver stiffness reduction followup
- 9 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.